Drug Trial Radar · NCT04996199
Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial
Last checked: Nov 19, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
132
Planned (sponsor's estimate)
Start
Sep 18, 2021
Primary completion
Dec 31, 2021
Study completion Jan 31, 2022
Sponsor
- Lead sponsor
- Postgraduate Institute of Dental Sciences RohtakAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Trigeminal neuralgia is a neuropathic facial pain condition, characterized by unilateral paroxysmal pain which can be described as stabbing or electric shock like, in the distribution of one or more divisions of trigeminal nerve which is triggered by innocuous stimuli. The attack is provoked by touching or stimulating these trigger zones. There are various pharmacological drugs present for the treatment of trigeminal neuralgia. Carbamazepine and oxcarbazepine are the first-choice drugs for the treatment of TN. Other drugs include lamotrigine , baclofen , gabapentin, antidepressants , eslicarbazepine , sumatriptan \& vixitrigine. The carbamazepine is first choice of drug which has serious side effects including dizziness, memory loss, sleppiness, aplastic anaemia. Oxcarbazepine has similar mechanism of action and found to have lesser adverse events when used in various neuralgias in the place of carbamazepine. But there is still lack of evidence to prove that oxcarbazepine can be used as monotherapy in TN patients.
Conditions
- Trigeminal Neuralgia
Interventions
OxcarbazepineDrug
oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
CarbamazepineDrug
carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pain scoresTime frame: 10 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
PGIDS
Rohtak, Haryana, India · Recruiting
Post Graduate Institute of Dental Sciences
Rohtak, Haryana, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.